248 related articles for article (PubMed ID: 30317416)
61. Non-Pharmacological Interventions in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Network Meta-analysis.
Li Y; He W; Jiang J; Zhang J; Ding M; Li G; Luo X; Ma Z; Li J; Ma Y; Shen Y; Han X
Arch Phys Med Rehabil; 2024 May; 105(5):963-974. PubMed ID: 37499852
[TBL] [Abstract][Full Text] [Related]
62. Maximum longitudinal relaxation velocity of the left ventricle: its clinical value and relationship with NT-proBNP plasma levels in heart failure.
Taléns-Visconti R; Rivera M; Climent V; Valero R; Martínez-Dolz L; Sancho-Tello MJ; Cortés R; Miro V; Sevilla B; Perez-Bosca JL; Bertomeu V; Salvador A; Jordan A; Marin F; Sogorb F
Echocardiography; 2006 Apr; 23(4):295-302. PubMed ID: 16640706
[TBL] [Abstract][Full Text] [Related]
63. Catheter ablation versus medical rate control for persistent atrial fibrillation in patients with heart failure: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials.
Zhu M; Zhou X; Cai H; Wang Z; Xu H; Chen S; Chen J; Xu X; Xu H; Mao W
Medicine (Baltimore); 2016 Jul; 95(30):e4377. PubMed ID: 27472728
[TBL] [Abstract][Full Text] [Related]
64. Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: a retrospective cross-sectional study.
Nah EH; Kim SY; Cho S; Kim S; Cho HI
BMJ Open; 2019 Apr; 9(4):e026030. PubMed ID: 31005928
[TBL] [Abstract][Full Text] [Related]
65. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
[TBL] [Abstract][Full Text] [Related]
66. Add-on Immunoadsorption Shortly-after Optimal Medical Treatment Further Significantly and Persistently Improves Cardiac Function and Symptoms in Recent-Onset Heart Failure-A Single Center Experience.
Weinmann K; Werner J; Koenig W; Rottbauer W; Walcher D; Keßler M
Biomolecules; 2018 Nov; 8(4):. PubMed ID: 30400209
[TBL] [Abstract][Full Text] [Related]
67. New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study.
Donal E; Lund LH; Oger E; Hage C; Persson H; Reynaud A; Ennezat PV; Bauer F; Drouet E; Linde C; Daubert C;
Eur J Heart Fail; 2015 Jul; 17(7):680-8. PubMed ID: 26033771
[TBL] [Abstract][Full Text] [Related]
68. Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction.
Ruddy JM; Kroman A; Baicu CF; Zile MR
Heart Fail Clin; 2024 Jan; 20(1):39-50. PubMed ID: 37953020
[TBL] [Abstract][Full Text] [Related]
69. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure.
Li X; Zhang J; Huang J; Ma A; Yang J; Li W; Wu Z; Yao C; Zhang Y; Yao W; Zhang B; Gao R;
J Am Coll Cardiol; 2013 Sep; 62(12):1065-1072. PubMed ID: 23747768
[TBL] [Abstract][Full Text] [Related]
70. Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis.
Khan MS; Siddiqi TJ; Usman MS; Sreenivasan J; Fugar S; Riaz H; Murad MH; Mookadam F; Figueredo VM
Int J Cardiol; 2018 Jul; 263():80-87. PubMed ID: 29685696
[TBL] [Abstract][Full Text] [Related]
71. Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure.
Mark DB; Cowper PA; Anstrom KJ; Sheng S; Daniels MR; Knight JD; Baloch KN; Davidson-Ray L; Fiuzat M; Januzzi JL; Whellan DJ; Piña IL; Ezekowitz JA; Adams KF; Cooper LS; O'Connor CM; Felker GM
J Am Coll Cardiol; 2018 Nov; 72(21):2551-2562. PubMed ID: 30466512
[TBL] [Abstract][Full Text] [Related]
72. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data.
Pufulete M; Maishman R; Dabner L; Higgins JPT; Rogers CA; Dayer M; MacLeod J; Purdy S; Hollingworth W; Schou M; Anguita-Sanchez M; Karlström P; Shochat MK; McDonagh T; Nightingale AK; Reeves BC
Syst Rev; 2018 Jul; 7(1):112. PubMed ID: 30064502
[TBL] [Abstract][Full Text] [Related]
73. Kidney Function, Nutritional Status, and the Left Ventricle Dysfunction Are Associated with Serum Uric Acid Levels in Patients with Heart Failure with Reduced Ejection Fraction.
Owczarek AJ; Choręza P; Arabzada H; Chudek J; Wojnicz R
Ann Clin Lab Sci; 2018 Sep; 48(5):608-613. PubMed ID: 30373865
[TBL] [Abstract][Full Text] [Related]
74. A Systematic Review and Meta-Analysis: Safety and Efficacy of Mesenchymal Stem Cells Therapy for Heart Failure.
Shen T; Xia L; Dong W; Wang J; Su F; Niu S; Wang Q; Fang Y
Curr Stem Cell Res Ther; 2021; 16(3):354-365. PubMed ID: 32867655
[TBL] [Abstract][Full Text] [Related]
75. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
[TBL] [Abstract][Full Text] [Related]
76. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
[TBL] [Abstract][Full Text] [Related]
77. Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial.
Gold MR; Van Veldhuisen DJ; Hauptman PJ; Borggrefe M; Kubo SH; Lieberman RA; Milasinovic G; Berman BJ; Djordjevic S; Neelagaru S; Schwartz PJ; Starling RC; Mann DL
J Am Coll Cardiol; 2016 Jul; 68(2):149-58. PubMed ID: 27058909
[TBL] [Abstract][Full Text] [Related]
78. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction.
Hage C; Bjerre M; Frystyk J; Gu HF; Brismar K; Donal E; Daubert JC; Linde C; Lund LH
Am J Cardiol; 2018 Jun; 121(12):1558-1566. PubMed ID: 29622288
[TBL] [Abstract][Full Text] [Related]
79. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction.
Abraham WT; Zile MR; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
JACC Heart Fail; 2015 Jun; 3(6):487-496. PubMed ID: 25982108
[TBL] [Abstract][Full Text] [Related]
80. Incremental value of N-terminal pro-brain natriuretic peptide over left ventricle ejection fraction and aerobic capacity for estimating prognosis in heart failure patients.
Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
J Heart Lung Transplant; 2008 Nov; 27(11):1251-6. PubMed ID: 18971099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
